WEIGUANG BIOLOGICAL(SZ:002880)2025-05-08 13:10Group 1: Plasma Collection and Supply - The company has implemented strategies to enhance plasma collection, including maintaining existing donors and expanding new donor recruitment, resulting in a plasma collection volume of 562 tons in 2024, an increase of 8.7% year-on-year [3][4] - Currently, the company operates 9 plasma collection stations, all fully operational, with plans to apply for new stations to increase collection capacity [3][4] - The company aims to ensure stable plasma supply by optimizing existing stations and actively seeking acquisition opportunities for quality plasma stations [8][9] Group 2: Research and Development - The company maintains a high level of R&D investment, which is crucial for sustaining technological leadership and competitive advantage, with a focus on enhancing the utilization rate of raw plasma and diversifying product offerings [4][5] - As of the end of 2024, the company has been granted 64 patents, including 24 invention patents and 40 utility model patents, reflecting its commitment to innovation [5] Group 3: Market Outlook and Value Creation - The global blood products industry is expected to grow due to increasing patient numbers and higher usage rates, with significant market potential in China as per capita usage remains low [8][9] - The company has a strategy to enhance its market value through cash dividends, stock bonuses, and employee stock ownership plans, while also focusing on investor relations and information disclosure [4][9]